Grifols (NASDAQ:GRFS) Shares Gap Down – Here’s Why

Grifols, S.A. (NASDAQ:GRFS)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $8.05, but opened at $7.74. Grifols shares last traded at $7.92, with a volume of 144,627 shares.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Up 3.9 %

The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. The stock has a market cap of $5.31 billion, a price-to-earnings ratio of 7.96 and a beta of 0.43. The company’s fifty day moving average price is $8.37 and its 200-day moving average price is $8.10.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GRFS. Tidal Investments LLC acquired a new stake in Grifols during the 3rd quarter valued at approximately $147,000. Sanctuary Advisors LLC acquired a new position in Grifols during the third quarter valued at $312,000. Geode Capital Management LLC grew its position in Grifols by 56.1% during the 3rd quarter. Geode Capital Management LLC now owns 110,532 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 39,733 shares during the period. Barclays PLC raised its stake in shares of Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock valued at $5,261,000 after buying an additional 469,401 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Grifols in the 3rd quarter valued at about $363,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.